Cancer immunotherapy targeting Wilms’ tumor gene WT1 product

References

• Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 60, 509–520 (1990).
   PubMed Web of Science ®Google Scholar
• Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774–778 (1990).
   PubMed Web of Science ®Google Scholar
• Gashler AL, Bonthron DT, Madden SL, Rauscher FJI, Collins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc. Natl Acad. Sci. USA 89, 10984–10988 (1992).
   PubMed Web of Science ®Google Scholar
• Harrington MA, Konicek B, Song A, Xia X-L, Fredericks WJ, Rauscher FJI. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms tumor locus. J. Biol. Chem. 268, 21271–21275 (1993).
   Google Scholar
• Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJI. Repression of the insulin-like growth Factor II gene by the Wilms tumor suppressor WT1. Science 257, 674–678 (1992).
   PubMed Web of Science ®Google Scholar
• Werner H, Re GG, Drummond IA et al. Increased expression of the insulin-like growth Factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc. Natl Acad. Sci. USA 9, 5828–5832 (1993).
   Google Scholar
• Englert C, Hou X, Maheswaran S et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 14, 4662–4675 (1995).
   Google Scholar
• Godyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms tumor suppressor gene product, wt1. Oncogene 10, 1125–1129 (1995).
   PubMedGoogle Scholar
• McCann S, Sullivan J, Guerra J, Arcinas M, Boxer LM. Repression of the c-myb gene by WT1 protein in T and B-cell lines. J. Biol. Chem. 270, 23785–23789 (1995).
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Hamada S, McDonnel TJ, Rauscher FJI, Saunders GF. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms tumor suppressor gene WT1. Cancer Res. 55, 5386–5389 (1995).
   Google Scholar
• Li RS, Law GL, Seifert RA, Romaniuk PJ, Morris DR. Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp. Cell Res. 247, 257–266 (1999).
   Google Scholar
• Zhang X, Xing G, Saunders GF. Proto-oncogene N-myc promoter is downregulated by the Wilms’ tumor suppressor gene WT1. Anticancer Res. 19, 1641–1648 (1999).
   Google Scholar
• Guan LS, Rauchman M, Wang ZY. Induction of Rb-associated protein (RbAp46) by Wilms’ tumor suppressor WT1 mediates growth inhibition. J. Biol. Chem. 273, 27047–27050 (1998).
   PubMed Web of Science ®Google Scholar
• Kim J, Prawitt D, Bardeesy N et al. The Wilms’ tumor suppressor gene (WT1) product regulates Dax-1 gene expression during gonadal differentiation. Mol. Cell Biol. 19, 2289–2299 (1999).
   Google Scholar
• Mayo MW, Wang CY, Drouin SS et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 18, 3990–4003 (1999).
   PubMed Web of Science ®Google Scholar
• Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE. Isolation, characterization, and expression of the murine Wilms tumor gene (WT1) during kidney development. Mol. Cell Biol. 11, 1707–1712 (1991).
   PubMed Web of Science ®Google Scholar
• Park S, Schalling M, Bernard A et al. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nature Genet. 4, 415–420 (1993).
   PubMed Web of Science ®Google Scholar
• Davies R, Moore A, Schedl A et al. Multiple roles for the Wilms’ tumor suppressor, WT1. Cancer Res. 59(Suppl. 7), S1747–S1750, discussion S1751 (1999).
   PubMedGoogle Scholar
• Moore AW, Mclnnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 126, 1845–1857 (1999).
   PubMedGoogle Scholar
• Miwa H, Beran M, Aunders GF. Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia 6, 405–409 (1992).
   PubMed Web of Science ®Google Scholar
• Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells. Leukemia 7, 970–977 (1993).
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H et al. WT1 as new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84, 3071–3079 (1994).
   PubMed Web of Science ®Google Scholar
• Bergmann L, Miething C, Maurer U et al. High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90, 1217–1225 (1997).
   PubMed Web of Science ®Google Scholar
• Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8, 2138–2143 (1994).
   PubMed Web of Science ®Google Scholar
• Menssen HD, Renkl H-J, Rodeck U et al. Presence of Wilms tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9, 1060–1067 (1995).
   PubMed Web of Science ®Google Scholar
• Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E. Detection by monoclonal antibodies of the Wilms’ tumor (WT1) nuclear protein in patients with acute leukemia. Int. J. Cancer 70, 518–523 (1997).
   Google Scholar
• Cilloni D, Gottardi E, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 2115–2121 (2002).
   PubMed Web of Science ®Google Scholar
• Tamaki H, Mishima M, Kawakami M et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int. J. Hematol. 78, 349–356 (2003).
   Google Scholar
• Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101, 1698–1704 (2003).
   PubMed Web of Science ®Google Scholar
• Greiner J, Ringhoffer M, Taniguchi M et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int. J. Cancer 108, 704–711 (2004).
   PubMed Web of Science ®Google Scholar
• Tamaki H, Ogawa H, Ohyashiki K et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13, 393–399 (1999).
   PubMed Web of Science ®Google Scholar
• Shichishima T, Okamoto M, Ikeda K et al. HLA class II haplotype and quantitation of the WT1 gene in Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (2005) (In Press).
   Google Scholar
• Oji Y, Ogawa H, Tamaki H et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer Res. 90, 194–204 (1999).
   PubMedGoogle Scholar
• Oji Y, Suzuki T, Nakano Y et al. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci. 95, 822–827 (2004).
   PubMedGoogle Scholar
• Oji Y, Inohara H, Nakazawa M et al. Overexpression of the Wilms’ tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci. 94, 523–529 (2003).
   PubMed Web of Science ®Google Scholar
• Oji Y, Miyoshi Y, Koga S et al. Overexpression of the Wilms’ tumor gene WT1 in primary thyroid cancer. Cancer Sci. 94, 606–611 (2003).
   PubMed Web of Science ®Google Scholar
• Oji Y, Yano M, Nakano Y et al. Overexpression of the Wilms’ tumor gene WT1 in esophageal cancer. Anticancer Res. 24, 3103–3108 (2004).
   PubMedGoogle Scholar
• Oji Y, Miyoshi S, Maeda H et al. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int. J. Cancer 100, 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Loeb DM, Evron E, Patel CB et al. Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res. 61, 921–925 (2001).
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Ando A, Egawa C et al. High expression of Wilms’ tumor suppressor gene (WT1) predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 8, 1167–1171 (2002).
   Google Scholar
• Oji Y, Nakamori S, Fujikawa M et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 95, 583–587 (2004).
   PubMed Web of Science ®Google Scholar
• Oji Y, Yamamoto H, Nomura M et al. Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 94, 712–717 (2003).
   PubMed Web of Science ®Google Scholar
• Ueda T, Oji Y, Naka N et al. Overexpression of the Wilms’ tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci. 94, 271–276 (2003).
   PubMedGoogle Scholar
• Oji Y, Miyoshi Y, Kiyotoh E et al. Absence of mutations in the Wilms’ tumor gene WT1 in primary breast cancer. Jpn. J. Clin. Oncol. 34, 74–77 (2004).
   PubMedGoogle Scholar
• Oji Y, Miyoshi S, Takahashi E et al. Absence of mutations in the Wilms’ tumor gene WT1 in de novo non-small cell lung cancers. Neoplasma 51, 17–20 (2004).
   PubMedGoogle Scholar
• Coppes MJ, Campbell CE, Williams BRG. The role of WT1 in Wilms tumorigenesis. FASEB J. 7, 886–895 (1993).
   PubMed Web of Science ®Google Scholar
• Rauscher FJI. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 7, 896–903 (1993).
   PubMed Web of Science ®Google Scholar
• Haber DA, Park S, Maheswaran S et al. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 262, 2057–2059 (1993).
   PubMed Web of Science ®Google Scholar
• Algar EM, Kenney MT, Simms LA, Smith SI, Kida Y, Smith PJ. Homozygous intragenic deletion in the WT1 gene in a sporadic Wilms’ tumour associated with high levels of expression of a truncated transcript. Hum. Mutat. 5, 221–227 (1995).
   Google Scholar
• Little M, Wells C. A clinical overview of WT1 gene mutations. Hum. Mutat. 9, 209–225 (1997).
   Google Scholar
• Loeb DM, Sukumar S. The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int. J. Hematol. 76, 117–126 (2002).
   PubMedGoogle Scholar
• Sugiyama H. Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int. J. Hematol. 73, 177–187 (2001).
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405–1412 (1997).
   PubMed Web of Science ®Google Scholar
• Harada Y, Nonomura N, Nishimura K et al. The WT1 expression in human testicular germ cell tumors. Mol. Urol. 3, 357–363 (1999).
   Google Scholar
• Yamagami T, Sugiyama H, Inoue K et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87, 2878–2884 (1996).
   PubMed Web of Science ®Google Scholar
• Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 12, 1005–1014 (1996).
   PubMed Web of Science ®Google Scholar
• Inoue K, Tamaki H, Ogawa H et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91, 2969–2976 (1998).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Ogawa H et al. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk. Res. 23, 499–505 (1999).
   Google Scholar
• Li H, Oka Y, Tsuboi A et al. The lck promoter-driven expression of the Wilms’ tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int. J. Hematol. 77, 463–470 (2003).
   PubMedGoogle Scholar
• Osaka M, Koami K, Sugiyama T. WT1 contributes to leukemogenesis: expression patterns in 7, 12-dimthylbenz[a]anthracence (DMBA)-induced leukemia. Int. J. Cancer 72, 696–699 (1997).
   PubMed Web of Science ®Google Scholar
• Hosen N, Sonoda Y, Oji Y et al. Very low frequencies of human normal CD34+ hematopoietic progenitor cells express the Wilms’ tumor gene WT1 at the levels comparable to those in leukemia cells. Br. J. Haematol. 116, 409–420 (2002).
   PubMed Web of Science ®Google Scholar
• Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms tumor gene WT1 product. J. Immunol. 164, 1873–1880 (2000).
   Google Scholar
• Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H. WT1 as a no novel target antigen for cancer immunotherapy. Curr. Cancer Drug Targets 2, 45–54 (2001).
   Google Scholar
• Tsuboi A, Oka Y, Ogawa H et al. Cytotoxic T-lymphocyte responses elicited to Wilms’ tumor gene WT1 product by DNA vaccination. J. Clin. Immuol. 20, 195–202 (2000).
   Google Scholar
• Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96, 1480–1489 (2000).
   PubMed Web of Science ®Google Scholar
• Gao L, Xue SA, Hasserjian R et al. Human cytotoxic T-lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75, 1429–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kawasaki K, Oka Y et al. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol. Immunother. 53, 617–624 (2004).
   PubMed Web of Science ®Google Scholar
• Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms’ tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99, 3272–3279 (2002).
   PubMed Web of Science ®Google Scholar
• Wu F, Oka Y, Tsuboi A et al. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19, 268–274 (2004).
   Google Scholar
• Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin. Cancer Res. 7, S761–S765 (2001).
   PubMedGoogle Scholar
• Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100, 2132–2137 (2002).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T-lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of wild type Wilms tumor gene WT1 product. Immunogenetics 51, 99–107 (2000).
   PubMed Web of Science ®Google Scholar
• Gao L, Bellantuono I, Elsasser A et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T-lymphocytes specific for WT1. Blood 95, 2198–2203 (2000).
   PubMed Web of Science ®Google Scholar
• Bellantuono I, Gao L, Parry S et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100, 3835–3837 (2002).
   PubMed Web of Science ®Google Scholar
• Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286–293 (2000).
   PubMed Web of Science ®Google Scholar
• Yasukawa M. Immunotherapy for leukemia targeting the Wilms’ tumor gene. Leuk. Lymphoma 42, 267–273 (2001).
   Google Scholar
• Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T-lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol. Immunother. 51, 614–620 (2002).
   PubMed Web of Science ®Google Scholar
• Azuma T, Makita M, Ninomiya K, Fujita S, Harada M, Yasukawa M. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted antileukaemia cytotoxic T-lymphocytes. Br. J. Haematol. 116, 601–603 (2002).
   Google Scholar
• Koesters R, Linnebacher M, Coy JF et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T-cells. Int. J. Cancer109, 385–392 (2004).
   PubMed Web of Science ®Google Scholar
• Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T-lymphocytes. Clin. Cancer Res. 10, 7402–7412 (2004).
   PubMed Web of Science ®Google Scholar
• Savage P, Gao L, Vento K et al. Use of B-cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103, 4613–4615 (2004).
   PubMedGoogle Scholar
• Knights AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DR-binding peptide derived from Wilms’ tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124–138)-pulsed dendritic cells generated according to an optimised protocol. Cancer Immunol. Immunother. 51, 271–281 (2002).
   PubMed Web of Science ®Google Scholar
• Muller L, Knights A, Pawelec G. Synthetic peptides derived from the Wilms’ tumor 1 protein sensitize human T-lymphocytes to recognize chronic myelogenous leukemia cells. Hematol. J. 4, 57–66 (2003).
   PubMedGoogle Scholar
• Oka Y, Tsuboi A, Murakami M et al. WT1 peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78, 56–61 (2003).
   PubMed Web of Science ®Google Scholar
• Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18, 165–166 (2004).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Osaka T et al. WT1 peptide-based immunotherapy for patients with lung cancer. Microbiol. Immunol. 48, 175–184 (2004).
   Google Scholar
• Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17, 1301–1312 (2003).
   PubMed Web of Science ®Google Scholar
• Xue S, Gao L, Gillmore R et al. WT1-targeted immunotherapy of leukaemia. Blood Cells Mol. Dis. 33, 288–290 (2004).
   PubMed Web of Science ®Google Scholar